The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShield Thera Regulatory News (STX)

Share Price Information for Shield Thera (STX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.90
Bid: 1.80
Ask: 2.00
Change: 0.375 (24.59%)
Spread: 0.20 (11.111%)
Open: 1.525
High: 1.90
Low: 1.90
Prev. Close: 1.525
STX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

24 Jul 2023 14:27

RNS Number : 9974G
Shield Therapeutics PLC
24 July 2023
 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BYV81293

Issuer Name

SHIELD THERAPEUTICS PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

Jupiter Fund Management PLC

City of registered office (if applicable)

London

Country of registered office (if applicable)

United Kingdom

4. Details of the shareholder

Name

City of registered office

Country of registered office

Northern Trust

5. Date on which the threshold was crossed or reached

21-Jul-2023

6. Date on which Issuer notified

24-Jul-2023

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

4.780000

0.000000

4.780000

34127697

Position of previous notification (if applicable)

6.700000

0.000000

6.700000

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB00BYV81293

34127697

4.780000

Sub Total 8.A

34127697

4.780000%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

 

Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

 

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Jupiter Fund Management Plc ( Chain 1)

0.000000

0.000000

0.000000%

Jupiter Fund Management Plc ( Chain 1)

Jupiter Fund Management Group Limited

0.000000

0.000000

0.000000%

Jupiter Fund Management Plc ( Chain 1)

Jupiter Asset Management Group Limited

0.000000

0.000000

0.000000%

Jupiter Fund Management Plc ( Chain 1)

Knightsbridge Asset Management Limited

0.000000

0.000000

0.000000%

Jupiter Fund Management Plc ( Chain 1)

Jupiter Investment Management Group Limited

0.000000

0.000000

0.000000%

Jupiter Fund Management Plc ( Chain 1)

Jupiter Asset Management Limited

4.780000

0.000000

4.780000%

Jupiter Fund Management Plc (Chain 2)

Merian Global Investors Limited

0.000000

0.000000

0.000000%

Jupiter Fund Management Plc (Chain 2)

Merian Global Investors (Jersey) Limited

0.000000

0.000000

0.000000%

Jupiter Fund Management Plc (Chain 2)

Merian Global Investors (Finance) Limited

0.000000

0.000000

0.000000%

Jupiter Fund Management Plc (Chain 2)

Merian Global Investors Holdings Limited

0.000000

0.000000

0.000000%

Jupiter Fund Management Plc (Chain 2)

Jupiter Investment Management Limited

0.000000

0.000000

0.000000%

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

 

12. Date of Completion

24.07.2023

13. Place Of Completion

London, UK

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLRIMJTMTTTBAJ
Date   Source Headline
14th Sep 20207:00 amRNSNotice of Results
28th Aug 202012:21 pmRNSTotal Voting Rights Update
6th Aug 20202:21 pmRNSAEGIS-H2H study reanalysis
31st Jul 20207:00 amRNSTotal Voting Rights update
16th Jul 20207:00 amRNSPT20 paper publication
30th Jun 20207:00 amRNSTotal Voting Rights Update
26th Jun 20207:00 amRNSAppointment of Non-Executive Director
18th Jun 20203:18 pmRNSResults of 2020 Annual General Meeting
3rd Jun 20207:00 amRNSFeraccru®/Accrufer® publications
29th May 202011:25 amRNSTotal Voting Rights Update
28th May 20207:00 amRNSInvestor presentations
26th May 20207:00 amRNSAppointment of Chairman
22nd May 20204:15 pmRNS2019 Annual Report and 2020 AGM Notice
21st May 20204:40 pmRNSSecond Price Monitoring Extn
21st May 20204:35 pmRNSPrice Monitoring Extension
21st May 20207:00 amRNSPreliminary Results
19th May 20207:00 amRNSNotice of Results
11th May 20201:15 pmEQSHardman & Co Research: Shield Therapeutics (STX): Reassuring trading update
1st May 20207:00 amRNSBusiness and trading update
30th Apr 20205:23 pmRNSTotal Voting Rights Update
27th Apr 20207:00 amRNSFurther re. Directorate Change
22nd Apr 20207:00 amRNSDirectorate Change
26th Mar 20204:42 pmRNSSecond Price Monitoring Extn
26th Mar 20204:36 pmRNSPrice Monitoring Extension
20th Mar 202011:36 amRNSHolding(s) in Company
17th Mar 20202:06 pmRNSSecond Price Monitoring Extn
17th Mar 20202:00 pmRNSPrice Monitoring Extension
17th Mar 20207:00 amRNSAEGIS-H2H study update
6th Mar 20207:00 amRNSInvestor Presentation
2nd Mar 20204:41 pmRNSBlock Listing Application
21st Feb 202011:14 amRNSHolding(s) in Company
28th Jan 202012:15 pmEQSHardman & Co Research: Shield Therapeutics (STX): Good demand for Feraccru in Europe
27th Jan 20207:00 amRNSBusiness and trading update
24th Jan 20207:00 amRNSInvestor presentations
14th Jan 20207:15 amEQSHardman & Co Research: Shield Therapeutics (STX): Taking on China
8th Jan 20207:00 amRNSChina licence agreement for Feraccru/Accrufer
12th Dec 20195:30 pmRNSEland Oil & Gas
29th Nov 20193:31 pmRNSHolding(s) in Company
25th Nov 20197:00 amRNSQCA Corporate Governance Code
30th Oct 20197:30 amEQSHardman & Co Research: Shield Therapeutics (STX): More choice for clinicians and patients
22nd Oct 20197:00 amRNSPositive results presented at UEG Week 2019
26th Sep 20197:00 amRNSInvestor Presentation
2nd Sep 20199:14 amEQSHardman & Co Research: Shield Therapeutics (STX): FDA approval ushers in a new era for Shield
29th Aug 20197:00 amRNSInvestor presentations
15th Aug 201910:17 amRNSDirector/PDMR Shareholding
7th Aug 20197:00 amRNSHalf-year Report
5th Aug 201911:22 amEQSHardman & Co Research: Shield Therapeutics (STX) FDA approval opens door to major US opportunity
31st Jul 20191:21 pmRNSNotice of Results
26th Jul 20192:05 pmRNSSecond Price Monitoring Extn
26th Jul 20192:00 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.